| Metabolic tumor volume for response prediction in advanced-stage Hodgkin lymphoma J Mettler, H Müller, CA Voltin, C Baues, B Klaeser, A Moccia, ... Journal of Nuclear Medicine 60 (2), 207-211, 2019 | 87 | 2019 |
| Value of bone marrow biopsy in Hodgkin lymphoma patients staged by FDG PET: results from the German Hodgkin Study Group trials HD16, HD17, and HD18 CA Voltin, H Goergen, C Baues, M Fuchs, J Mettler, S Kreissl, J Oertl, ... Annals of Oncology 29 (9), 1926-1931, 2018 | 55 | 2018 |
| FDG-PET Imaging for Hodgkin and Diffuse large B-cell lymphoma—An updated overview CA Voltin, J Mettler, J Grosse, M Dietlein, C Baues, C Schmitz, ... Cancers 12 (3), 601, 2020 | 47 | 2020 |
| Outcome-based interpretation of early interim PET in advanced-stage Hodgkin lymphoma C Kobe, H Goergen, C Baues, G Kuhnert, CA Voltin, J Zijlstra, O Hoekstra, ... Blood, The Journal of the American Society of Hematology 132 (21), 2273-2279, 2018 | 40 | 2018 |
| Early response to first-line anti–PD-1 treatment in hodgkin lymphoma: A PET-based analysis from the prospective, randomized phase II NIVAHL trial CA Voltin, J Mettler, L van Heek, H Goergen, H Müller, C Baues, U Keller, ... Clinical Cancer Research 27 (2), 402-407, 2021 | 29 | 2021 |
| Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma–Data from the prospective, multicenter phase III HD16 trial L van Heek, C Stuka, H Kaul, H Müller, J Mettler, F Hitz, C Baues, M Fuchs, ... BMC cancer 22 (1), 672, 2022 | 20 | 2022 |
| Influences on PET quantification and interpretation JMM Rogasch, F Hofheinz, L van Heek, CA Voltin, R Boellaard, C Kobe Diagnostics 12 (2), 451, 2022 | 18 | 2022 |
| Dual-tracer PET/CT protocol with [18F]-FDG and [68Ga] Ga-FAPI-46 for cancer imaging: a proof of concept KS Roth, CA Voltin, L van Heek, S Wegen, K Schomäcker, T Fischer, ... Journal of Nuclear Medicine 63 (11), 1683-1686, 2022 | 16 | 2022 |
| Quantitative assessment of 18F-FDG PET in patients with Hodgkin lymphoma: is it significantly affected by contrast-enhanced computed tomography attenuation correction? CA Voltin, J Mettler, R Boellaard, G Kuhnert, M Dietlein, P Borchmann, ... Nuclear Medicine Communications 40 (3), 249-257, 2018 | 12 | 2018 |
| Involved-field radiation therapy prevents recurrences in the early stages of Hodgkin lymphoma in PET-negative patients after ABVD chemotherapy: Relapse analysis of GHSG Phase 3 … C Baues, H Goergen, M Fuchs, J Rosenbrock, E Celik, H Eich, C Kobe, ... International Journal of Radiation Oncology* Biology* Physics 111 (4), 900-906, 2021 | 6 | 2021 |
| Outcome prediction in patients with large B-cell lymphoma undergoing chimeric antigen receptor T-cell therapy CA Voltin, P Gödel, L Beckmann, JM Heger, C Kobe, N Kutsch, ... HemaSphere 7 (1), e817, 2023 | 5 | 2023 |
| Metabolic tumor volume for early response assessment in early-stage unfavorable Hodgkin lymphoma treated with nivolumab in the GHSG Nivahl phase II trial CA Voltin, J Mettler, H Mueller, M Fuchs, C Baues, M Dietlein, A Engert, ... Blood 134, 4020, 2019 | 4 | 2019 |
| Prognostic value of baseline metabolic tumor volume (MTV) for forecasting chemotherapy outcome in early‐stage unfavorable Hodgkin lymphoma: Data from the phase III HD17 trial L van Heek, J Weindler, C Gorniak, H Kaul, H Müller, J Mettler, C Baues, ... European Journal of Haematology 111 (6), 881-887, 2023 | 3 | 2023 |
| Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in different cancer types, resulting in larger … S Wegen, J Weindler, CA Voltin, L van Heek, K Schomäcker, T Fischer, ... Strahlentherapie und Onkologie 200 (1), 28-38, 2024 | 2 | 2024 |
| Long‐term remission in a patient with relapsed Richter's transformation treated with CD19‐directed chimeric antigen‐receptor T‐cells after allogeneic stem cell transplantation N Kutsch, P Gödel, CA Voltin, M Hallek, C Scheid, P Borchmann, ... European Journal of Haematology 112 (6), 984-987, 2024 | 1 | 2024 |
| International benchmark for total metabolic tumor volume assessment in baseline FDG PET/CT of lymphoma patients. R Boellaard, I Buvat, L Ceriani, AS Cottereau, L Guerra, R Hicks, ... Journal of Nuclear Medicine 64 (supplement 1), P83-P83, 2023 | 1 | 2023 |
| Staging Hodgkin Lymphoma Using PET-Can We Safely Exclude Bone Marrow Involvement? C Kobe, CA Voltin, C Baues, M Fuchs, M Dietlein, A Engert, P Borchmann, ... Journal of Nuclear Medicine 58 (supplement 1), 565-565, 2017 | 1 | 2017 |
| Fritz Kahn and the Centenary of The Doctor of the Future CA Voltin, LS Zuckier JAMA, 2024 | | 2024 |
| Baseline Metabolic Tumour Volume (MTV) as prognostic marker for forecasting Chemotherapy Outcome in Early-Stage Unfavourable Hodgkin Lymphoma: Data from the Phase III HD17 Trial K Roth, L van Heek, J Weindler, C Gorniak, H Kaul, H Müller, J Mettler, ... Nuklearmedizin-NuclearMedicine 63 (02), L30, 2024 | | 2024 |
| Evaluating GPT-4's performance in oncologic disease classification based on PET/CT reports of lymphoma patients: Are large language models the long-awaited'magic bullet'? C Voltin, M Dietlein, J Kottlors, P Borchmann, P Gödel, PJ Bröckelmann, ... Nuklearmedizin-NuclearMedicine 63 (02), P80, 2024 | | 2024 |
